IDSA and HIVMA strongly oppose government interference in the patient-health care provider relationship and religious refusal laws and regulations that allow health care professionals, employers, systems or insurers to deny access to services based on their own personal religious beliefs.
IDSA supports decisions by the Food and Drug Administration and the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices to authorize and recommend boosters meant to curb cases of more highly infectious strains of COVID-19.
IDSA and HIVMA are immensely grateful for Dr. Anthony Fauci’s contributions to the identification, treatment and containment of infectious diseases through his 38 years of leadership of the National Institute of Allergy and Infectious Diseases.
The nation’s leading infectious diseases professional society, recognizes the distinguished physicians and scientists from the United States and around the world who were elected this year to be Fellows of IDSA.
IDSA and HIVMA say that while barriers to ending the HIV epidemic are significant, the goal could be within reach with broad-based policy reforms at the federal, state and local levels.
Updated recommendations from the Centers for Disease Control and Prevention on masking and isolation post-COVID-19 infection are a positive sign that advances in vaccines and treatments have significantly lowered the risk of severe illness, hospitalization and death from the disease.
IDSA applauds new legislation introduced by Rep. Sean Patrick Maloney (D-NY) to ensure monkeypox testing is available at no cost to the public.
IDSA and HIVMA support the Biden Administration’s decision to declare the monkeypox outbreak a public health emergency.
As monkeypox cases top more than 5,800 across 48 states, there is no time to waste.
IDSA is pleased to see that critical new investments to strengthen the federal fight against antimicrobial resistance were included in the fiscal year 2023 Labor, Health and Human Services appropriations bill released July 28.
Today’s U.S. Department of Health and Human Services announcement that nearly 800,000 additional doses of the monkeypox vaccine are now available for distribution is a welcome development, but much more is urgently needed.
IDSA and HIVMA appreciate the CDC’s swift action in responding to health care provider concerns regarding the significant procedural barriers required to obtain tecovirimat, or TPOXX, through the Expanded Access for Investigational New Drug program.